LAPIX Therapeutics has dosed the first patient in a Phase 1b trial of LPX-TI641, an oral immunomodulator, for rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.